Today at DIA: Deloitte, Intermountain Launch OutcomesMiner Solution

BOSTON, June 24, 2013 -- Today at the Drug Information Association's 2013 Annual Meeting, Deloitte and Intermountain Healthcare announce the launch of OutcomesMiner, an analytics tool designed to give researchers, pharmaceutical and medical device companies the data-driven insight needed to conduct comparative effectiveness research and bring new therapies to market more rapidly.

Leveraging electronic medical records (EMR) data, OutcomesMiner helps users understand associated outcomes for treatments and filter for sub-populations using phenotypic characteristics and specific medical associations.  The solution draws upon Intermountain's vast repository of electronic health records (EHRs) in supporting analysis around patient and product outcomes under a double-blinded format designed to protect the privacy of personal health information. 

OutcomesMiner also enables users to conduct follow-on studies in developing further evidence to support comparative effectiveness research programs, new product planning activities, health economic and outcomes research and observational insights that support safety analytics and commercial decision making.  In addition to the benefits for life sciences companies, OutcomesMiner can help hospitals and clinics determine better treatments based on clinical data and patient characteristics.

"The life sciences and health care industry is entering a new era in which success is tied to demonstrating value for reimbursement with an increased focus on safety and clinical effectiveness," said Brett Davis, general manager of Deloitte Health Informatics (DHI).  "OutcomesMiner can help our clients thrive under this new paradigm by providing the insights they need based on rigorous real-world evidence."

Asif Dhar, M.D., chief medical officer and managing director of DHI, said, "With OutcomesMiner, we aspire to create a solution that is transformative, one that can support the health system as it undergoes fundamental change based on insights generated from EHR data."  He continued, "Tackling the issues vexing today's health system requires new approaches based on the smart use of data."

Marc Probst, chief information officer of Intermountain, said users of OutcomesMiner will be able to form "research communities" that develop additional insights related to comparative effectiveness and evidence-based medicine. "OutcomesMiner can do more than provide insights in a one-off manner," said Probst.  "It can also be the catalyst that brings key players together in further exploring new approaches to health care based on data."

About Deloitte's Life Sciences and Health Care Practice
Deloitte's life sciences and health care practice brings fresh insight to clients and industry stakeholders.  Deloitte offers a distinctive menu of professional services delivered in an integrated approach that address all segments of the health plan, health provider and life sciences industries. For more information, visit www.deloitte.com/view/en_US/us/Industries/index.htm.

About Intermountain Healthcare
Intermountain Healthcare is a Utah-based nonprofit system of 22 hospitals, 200 clinics, a medical group with some 1,100 employed physicians, a health plans division called SelectHealth, and other health services. Intermountain is widely recognized as a leader in transforming health care through high quality and sustainable costs.  For more information about Intermountain, visit www.intermountainhealthcare.org.

As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP.  Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

As used in this document, "Deloitte" means Deloitte & Touche LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte LLP and its subsidiaries. Certain services may not be available to attest clients under the rules and regulations of public accounting.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.